Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials
Aim/Background: After the introduction of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC), different studies tried to evaluate whether other systemic therapies can improve survival. To provide a comprehensive indirect treatment comparison of efficacy and safety of novel drugs, a network meta-analysis (NMA) of phase III randomized controlled trials was performed.Methods: After pertinent literature search up to November 1, 2016, 6 studies were eligible for the analysis including 4,812 individual patients with advanced HCC: 2,454 received sorafenib, 577 received brivanib, 530 received sunitinib, 514 rece...
Source: Liver Cancer - October 18, 2017 Category: Cancer & Oncology Source Type: research

Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function
We examined the efficacy of this grading system for determining hepatic function in patients with hepatocellular carcinoma (HCC).Methods/Materials: The prognoses of 46,681 HCC patients based on results obtained from a nationwide survey conducted in Japan from 2001 to 2007 were evaluated using (1) Japan Integrated Staging (JIS), consisting of Child-Pugh classification and TNM staging (TNM), (2) modified JIS (m-JIS), consisting of liver damage grading and TNM, and (3) ALBI-TNM (ALBI-T), consisting of ALBI grading and TNM, and the results were compared. A subanalysis was also performed to define a cutoff value for ALBI scores...
Source: Liver Cancer - September 21, 2017 Category: Cancer & Oncology Source Type: research

Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study
Background: Level I evidence supports the use of sorafenib in patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma, where heterogeneity in efficacy exists due to varying clinicopathologic features of the disease.Aim: We evaluated whether prior treatment with curative or locoregional therapies influences sorafenib-specific survival.Methods: From a prospective data set of 785 consecutive patients from international specialist centres, 264 patients (34%) were treatment na ïve (TN) and 521 (66%) were pre-treated (PT), most frequently with transarterial chemoembolization (n = 413; 79%). The prima...
Source: Liver Cancer - September 15, 2017 Category: Cancer & Oncology Source Type: research

Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting
Background: Stereotactic body radiation therapy (SBRT) is an advanced technique of external beam radiation therapy that delivers large ablative doses of radiation. In the past decade, many cancer centers have adopted SBRT as one mode of radically treating small-sized hepatocellular carcinoma (HCC), based on encouraging clinical outcomes. SBRT thus seems reasonable as first-line treatment of inoperable HCC confined to the liver. However, most of the clinical studies to date have been retrospective in nature, with key issues still under investigation.Summary: The above-mentioned publications were subjected to scrutiny, fueli...
Source: Liver Cancer - August 29, 2017 Category: Cancer & Oncology Source Type: research

Association of Serum Ferritin with Diabetes and Alcohol in Patients with Non-Viral Liver Disease-Related Hepatocellular Carcinoma
Conclusion: In patients with nvHCC, serum ferritin levels are higher in non-diabetics and alcoholics.Liver Cancer 2017;6:307-312 (Source: Liver Cancer)
Source: Liver Cancer - August 28, 2017 Category: Cancer & Oncology Source Type: research

Clinical Factors Predicting Better Survival Outcome for Pulmonary Metastasectomy of Hepatocellular Carcinoma
This study aims to identify clinical factors that may be used to guide patient selection for such a therapeutic modality. A total of 28 patients who received pulmonary metastasectomy for HCC between 1993 and 2012 were identified. All relevant clinical factors were extracted from medical records up to September 2015. Patients were classified into high- and low-risk groups according to survival outcome after metastasectomy. All pertinent clinical factors were analyzed for correlation with survival outcome.Summary: The overall survivalof 28 patients after pulmonary metastasectomy was studied first. The survival curve was biph...
Source: Liver Cancer - August 28, 2017 Category: Cancer & Oncology Source Type: research

An Ecological Study of the Association between Air Pollution and Hepatocellular Carcinoma Incidence in Texas
Introduction: Primary liver cancer is a significant cause of cancer-related death in both the United States and the world at large. Hepatocellular carcinoma comprises 90% of these primary liver cancers and has numerous known etiologies. Evaluation of these identified etiologies and other traditional risk factors cannot explain the high incidence rates of hepatocellular carcinoma in Texas. Texas is home to the second largest petrochemical industry and agricultural industry in the nation; industrial activity and exposure to pathogenic chemicals have never been assessed as potential links to the state's increased incidence ra...
Source: Liver Cancer - August 28, 2017 Category: Cancer & Oncology Source Type: research

Sorafenib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombosis
Conclusion: For the treatment of HCC with Vp3/Vp4, it is desirable to initially use LFP and then immediately change to sorafenib if no response is obtained.Liver Cancer 2017;6:275-286 (Source: Liver Cancer)
Source: Liver Cancer - August 28, 2017 Category: Cancer & Oncology Source Type: research

Lenvatinib in Advanced Hepatocellular Carcinoma
Liver Cancer 2017;6:253-263 (Source: Liver Cancer)
Source: Liver Cancer - August 28, 2017 Category: Cancer & Oncology Source Type: research

Title Page / Table of Contents
Liver Cancer 2017;6(suppl 1):I-IV (Source: Liver Cancer)
Source: Liver Cancer - July 13, 2017 Category: Cancer & Oncology Source Type: research

The 8th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2017). The Art & Science of Conquering Liver Cancer. Singapore, July 14-16, 2017: Abstracts
Liver Cancer 2017;6(suppl 1):1-71 (Source: Liver Cancer)
Source: Liver Cancer - July 13, 2017 Category: Cancer & Oncology Source Type: research

Information of APPLE 2017
Liver Cancer 2017;6:252 (Source: Liver Cancer)
Source: Liver Cancer - June 6, 2017 Category: Cancer & Oncology Source Type: research

The APPLE Association President's Message
Liver Cancer 2017;6:251 (Source: Liver Cancer)
Source: Liver Cancer - June 6, 2017 Category: Cancer & Oncology Source Type: research

Apple News
Liver Cancer 2017;6:250 (Source: Liver Cancer)
Source: Liver Cancer - June 6, 2017 Category: Cancer & Oncology Source Type: research

Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) usually develops in chronically damaged liver. We investigated hepatic reserves during chemotherapy of patients with advanced HCC and compensated liver function to evaluate the effect on patients' outcomes of maintaining hepatic reserve after chemotherapy. We retrospectively reviewed the medical records of 190 patients with Child-Pugh A with advanced HCC who were treated with sorafenib or hepatic arterial infusion chemotherapy (HAIC). We investigated the Child-Pugh score and albumin-bilirubin grade for hepatic reserve, and evaluated the effect of the change in Child-Pugh scores on patients' o...
Source: Liver Cancer - May 16, 2017 Category: Cancer & Oncology Source Type: research